Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129337 · ClinicalTrials.gov registry record · Phase 1
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
A Phase 1 study of Tumors, sponsored by Peregrine Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 6
- Study locations
NCT00129337 is a Phase 1 study of Tumors that has completed, run by Peregrine Pharmaceuticals. The registered enrollment target is 28 participants, below the 198-participant average among 20 other Tumors trials with a reported enrollment target (86% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT00129337, a Phase 1 study of Tumors, has completed, sponsored by Peregrine Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine the safety of bavituximab when administered via a vein, and to examine how bavituximab behaves in the body - how quickly it is taken up by the body and how long it stays there. The effect of bavituximab on tumor responses will also be examined.
Conditions Studied
Interventions
- DRUG Bavituximab
Study Locations (6)
Texas
- University of Texas Southwestern Medical Center - Dallas
- MD Anderson Cancer Center - Houston
- Scott & White Hospital, Center for Cancer Prevention and Care - Temple
Arizona
- Arizona Cancer Center - Tucson
California
- Premiere Oncology - Santa Monica
Tennessee
- The West Clinic - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00129337
The ClinicalTrials.gov registry entry for NCT00129337 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 20 other Tumors trials with a reported enrollment target (86% lower). The listed sponsor is Peregrine Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Bavituximab is the first listed.
NCT00129337 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Texas, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00129337 about?
NCT00129337 is a clinical study titled "Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies". The purpose of this study is to determine the safety of bavituximab when administered via a vein, and to examine how bavituximab behaves in the body - how quickly it is taken up by the body and how long it stays there. The effect of bavituximab on tumor responses will also be examined.
What is the current status of trial NCT00129337?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2005-06. Estimated completion is 2009-08.
What conditions does trial NCT00129337 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT00129337?
The interventions under investigation include: Bavituximab (DRUG).
Who is sponsoring clinical trial NCT00129337?
This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00129337 being conducted?
This trial has 6 study locations across Arizona, California, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
-
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.